Deals
Teva Set to Resume Deals After Investors Reward Rivals: Real M&A
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. may need to jump on the takeover bandwagon soon.
The $48 billion company’s top-selling medicine will have to compete with cheaper generic copies beginning later this year, which will eventually eat into profits. The problem of patent expirations and sluggish growth isn’t unique to Teva, whose peers are opting for big, accretive acquisitions -- bets that are paying off and restoring enthusiasm for their stocks.